Search the Newsreel

Jupiter Life Line Hospitals releases Q1 FY27 earnings call transcript

Jupiter Neurosciences, Inc. (JUNS) Stock Price, News, Quote & History

Jupiter Neurosciences, Inc. (JUNS) stock was trading at $5.30, down 5.90%, as of 1:45:04 p.m. EDT. The company announced a 1-for-75 reverse stock split effective August 7, 2026. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing therapeutics for central nervous system disorders …

Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com

This article reports on a Form 8K filing by Jupiter Neurosciences Inc. for August 6th. The content is very brief, mainly consisting of the headline and a reference to Reuters, indicating it's an announcement of the filing rather than an analysis of its contents. …

Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading

Jupiter Neurosciences (JUNS) has granted 472,222 stock options to director Andrew Jon Cutler under its 2025 Equity Incentive Plan. This grant, with an exercise price of $0.0900 per share, is in lieu of cash compensation for his board service. The options vest with 25% …

Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced a 1-for-75 reverse stock split, approved by its board of directors and stockholders. This action is intended to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding …

Earnings Beat: Jupiter Life Line Hospitals Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jupiter continues 2026 buyback, cuts share count to 518.1m

Form 8.3 - LondonMetric Property Plc

Jupiter Asset Management FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Jupiter Fund Management Plc (b) Owner …

Kaskela Law Firm Announces Stockholder Investigation of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) and Encourages Long-Term JUNS Investors to Contact the Firm

Kaskela Law LLC has initiated an investigation into Jupiter Neurosciences, Inc. (NASDAQ:JUNS) on behalf of its shareholders. The firm is looking into whether Jupiter and its officers/directors violated securities laws or breached fiduciary duties. Long-term JUNS investors are encouraged to contact Kaskela Law LLC …

Jupiter Neurosciences expands into psychedelics with $100m deal

Jupiter Neurosciences has acquired exclusive US rights to ALA-002, a clinical-stage psychedelic therapy candidate, for up to $100 million, marking its expansion into neuropsychiatric disorders. This move adds a second clinical program to Jupiter's portfolio, alongside therapies for Parkinson's disease, and signals a broader …

Form 8.3 -Rotork plc

Jupiter Asset Management FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Jupiter Fund Management Plc (b) Owner …

Jupiter Life Line Hospitals Q1 FY27 Results: PAT Rs 37 Cr, Revenu

Jupiter Life Line Hospitals Q1 Results: Revenue up 16% YoY to ₹4,109.83 million

Earnings call transcript: Jupiter Life Line Hospitals posts solid Q1 2027, stock swings lower

Jupiter Neurosciences (JUNS) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Jupiter Neurosciences (JUNS). It likely covers aspects such as price targets, current recommendations from analysts, and potential future performance. Investors can use this information to inform their decisions regarding the stock.

Jupiter Mines Ends FY2026 Strong as Tshipi Manganese Output and Sales Beat Expectations

JLHL: Q1FY27 revenue rose 16.2% year-over-year, but PAT fell 14.7% amid expansion costs

JUNS|Jupiter Neurosciences Inc|Price:0.099|Chg%:-0.000

This article provides a comprehensive stock analysis of Jupiter Neurosciences Inc (JUNS) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and current fair valuation. Despite recent weak stock market performance, the company shows strong technicals and has a high institutional ownership.

One Mining Stock Well Placed to Navigate through COVID-19 Uncertainties - Jupiter Mines Limited

Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA

Jupiter Neurosciences, Inc. issued and sold 11.47 million shares of common stock to YA II PN, Ltd. (Yorkville) between May 14, 2026, and July 24, 2026, under a Standby Equity Purchase Agreement (SEPA), generating approximately $3.6 million in gross proceeds. The company's reliance on …

Jupiter Neurosciences Inc (JUNS) Dividends & Stock Splits: Historical Payouts and Event Timeline

Jupiter Neurosciences Inc (JUNS) has not distributed any dividends over the past five years. The article provides current trading information for JUNS, showing a stock price of $0.114 USD, down 6.03%, with a market capitalization of $4.13 million. The company's dividend history section currently …

Jupiter Neurosciences Inc (JUNS) Cash Flow

This article provides the quarterly and annual cash flow statements for Jupiter Neurosciences Inc (JUNS), allowing users to evaluate the company's financial health. It details operating, investing, and financing cash flows, along with related metrics and definitions. The data shows changes in cash flow …

Jupiter Neurosciences, Inc. Files Form 8-K: Key Details on Nasdaq Listing, Address, and Corporate Status

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced the results of its 2026 Annual Meeting, where shareholders approved all director nominees, ratified the independent auditor, and increased shares for the equity incentive plan. Critically, shareholders also approved a potential reverse stock split (1-for-10 to 1-for-100) to …

Jupiter Neurosciences (NASDAQ: JUNS) details Yorkville SEPA terms

Jupiter Neurosciences (JUNS) held its 2026 Annual Meeting, where stockholders approved the election of directors, ratified Cherry Bekaert LLC as independent accountants, amended the 2025 Equity Incentive Plan, and approved a reverse stock split. The company also detailed its Standby Equity Purchase Agreement (SEPA) …

Jupiter Life Line Hospitals Schedules Q1 FY27 Earnings Call for August 3

Jupiter Fund Management Plc 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:JFHHF) 2026-07-27

Key Points Interested in Jupiter Fund Management Plc? Here are five stocks we like better. Jupiter reported a strong interim period with assets under management reaching a record GBP 73.7 billion, up 36% from year-end, helped by positive net inflows and better investment performance. …

Jupiter Neurosciences Inc (JUNS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey concerns Jupiter Neurosciences Inc (JUNS) and its revenue breakdown by business segments and regional contributions. However, the article states that relevant data for these breakdowns have not been disclosed by the company yet. It provides basic stock information for JUNS, …

TradingKey

This article provides a detailed balance sheet analysis for Jupiter Neurosciences Inc (JUNS), presenting both quarterly and annual financial metrics. It covers various asset, liability, and equity categories, allowing investors to evaluate the company's financial health, liquidity, and leverage. The financial data highlights changes …

Jupiter Neurosciences Inc (JUNS) Valuation: PE, PB & Fair Value Analysis

Form 8.3 -A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited

Jupiter Asset Management FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Jupiter Fund Management Plc (b) Owner …

Why Jupiter Mines (ASX:JMS) Stock Is Moving Higher

Jupiter Energy Reports $3.178 Million in Oil Sales for June Quarter as Kazakh Production Remains on Track

Jupiter Energy Posts $3.178 Million in Q2 Oil Sales as Kazakh Production Progresses Steadily